CLAIMS

1. A stabilized vaccine composition comprising:

a. at least one polypeptide-polysaccharide conjugate, wherein the polypeptide component of the at least one polypeptide-polysaccharide conjugate comprises at least two non-natural amino acids (nnAA);

b. an aluminum adjuvant;

c. a non-aluminum phosphate salt; and

d. sodium chloride;

wherein the concentration of sodium chloride is less than 200 mM, and the pH is between about 5.5 and 7.

2. The stabilized vaccine composition of claim 1, further comprising an emulsifier.

3. The stabilized vaccine composition of claims 1 or 2, wherein:

a. the polypeptide component of the at least one polypeptide-polysaccharide conjugate is a substituted polypeptide antigen or a carrier protein; and /or

b. the polysaccharide component of the at least one polypeptide-polysaccharide conjugate is a capsular polysaccharide.

4. The stabilized vaccine composition of claim 3, wherein the capsular polysaccharide is a capsular polysaccharide of *Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae, or Streptococcus pyogenes.*

5. The stabilized vaccine composition of any one of claims 1 to 4, wherein the at least one polypeptide-polysaccharide conjugate comprises at least 20 distinct polypeptide-polysaccharide conjugates.

6. The stabilized vaccine composition of claim 5, wherein the at least 20 distinct polypeptide-polysaccharide conjugates comprise at least 24 or at least 31 distinct polypeptide-polysaccharide conjugates; wherein there is a distinct polypeptide-polysaccharide conjugate comprising a capsular polysaccharide for each of *Streptococcus pneumoniae* serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 9N, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20B, 22F, 23F, and 33F.

7. The stabilized vaccine composition of any one of claims 1-6, wherein the at least two nnAAs are pAMF.

8. The stabilized vaccine composition of any one of claims 1-7, wherein the polypeptide component of the polypeptide-polysaccharide conjugate comprises an amino acid sequence that is at least 80% identical to SEQ ID NO: 1.

9. The stabilized vaccine composition of any one of claims 1-8, wherein the polypeptide component of the polypeptide-polysaccharide conjugate comprises or consists of the amino acid sequence of SEQ ID NO: 2.

10. The stabilized vaccine composition of any one of claims 1-9, wherein the aluminum adjuvant is aluminum phosphate (ALPO), aluminum hydroxide (ALOH), amorphous aluminum hydroxyphosphate sulfate, or aluminum potassium phosphate.

11. The stabilized vaccine composition of any one of claims 1-10, wherein the concentration of the aluminum adjuvant is between about 125 µg/mL and about 250 µg/mL, and /or wherein the concentration of the non-aluminum phosphate salt is between about 15 mM and 20 mM.

12. The stabilized vaccine composition of any one of claims 1-11, wherein the stabilized vaccine composition comprises a liquid solution and an alum suspension.

13. The stabilized vaccine composition of claim 12, wherein the alum suspension comprises or consists of particles with a D50 value of between about 1 µm and about 10 µm.

14. Use of the stabilized vaccine composition of any one of claims 1-13 in the manufacture of a medicament for inducing a protective immune response against an infectious pathogen in a subject.

15. The use of claim 14, wherein the infectious pathogen is *S. pneumoniae* or *S. pyogenes.*